Arcus Biosciences RCUS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $222M+48.0% | $150M+18.1% | $127M-38.3% | $206M+39.2% | ||
| $759M-8.3% | $828M+31.0% | $632M-21.3% | $803M+129% | ||
| $1.01B-0.9% | $1.02B+22.3% | $831M-22.1% | $1.07B-15.5% | ||
| $40M-14.9% | $47M-7.8% | $51M+45.7% | $35M+9.4% | ||
| $1.14B-1.0% | $1.15B+5.0% | $1.1B-18.6% | $1.35B-15.5% | ||
| $42M+133% | $18M+5.9% | $17M-15.0% | $20M+100% | ||
| $35M-58.8% | $85M-6.6% | $91M-6.2% | $97M-4.9% | ||
| $231M+2.2% | $226M+22.8% | $184M-4.7% | $193M+16.3% | ||
| $99M+106% | $48M— | $0— | —— | ||
| 400M-75.3% | 1.6B+23.3% | 1.3B+8.7% | 1.2B+7.9% | ||
| -$1.49B-31.2% | -$1.13B-33.3% | -$849M-56.6% | -$542M-97.1% | ||
| $631M+30.1% | $485M+5.0% | $462M-29.7% | $657M-22.0% | ||
| $1.14B-1.0% | $1.15B+5.0% | $1.1B-18.6% | $1.35B-15.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Arcus Biosciences cover its short-term obligations?
- Its current ratio is 4.04 — current assets exceed current liabilities.
- Where does Arcus Biosciences's balance sheet data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.